Product image of Havrix Junior (Hepatitis A Virus (Inactivated), Algeldrate) supplied by GNH India

Havrix Junior

Active Ingredient:
Hepatitis A Virus (Inactivated), Algeldrate
Origin:
EU

Havrix Junior (Hepatitis A Virus (Inactivated), Algeldrate)

Havrix Junior is a pediatric hepatitis A vaccine that contains inactivated hepatitis A virus antigen combined with the adjuvant algeldrate. It is supplied as an injectable solution for intramuscular administration. The product is authorized in the European Union and is available by prescription only. Havrix Junior is formulated to induce active immunity against hepatitis A infection in children, providing a safe and effective preventive measure.

Manufacturer / TM Owner

Glaxosmithkline Biologicals S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Havrix Junior is indicated for the active immunization of children against hepatitis A virus infection.

  • Administration to children aged 12 months and older as part of a primary vaccination series.
  • Use in combination with other routine childhood vaccines when schedule permits.
  • Providing protection in regions with intermediate or high hepatitis A endemicity.
  • Supporting travel health recommendations for pediatric travelers to areas with hepatitis A risk.
  • Facilitating outbreak control measures in school or community settings.

Side Effects

The safety profile of Havrix Junior reflects the typical reactions observed with inactivated viral vaccines.

Common

  • Injection site pain, redness or swelling.
  • Mild fever.
  • Headache.
  • Fatigue.

Serious

  • Severe allergic reaction (anaphylaxis).
  • High fever lasting more than 48 hours.
  • Neurological symptoms such as seizures (rare).

Precautions & Warnings

Before administering Havrix Junior, healthcare providers should review the child’s medical history and consider specific safety considerations.

  • Known hypersensitivity to any vaccine component, including algeldrate, should contraindicate use.
  • Post‑vaccination fever may require antipyretic treatment.
  • Delay vaccination in children with acute moderate or severe illness.
  • Observe the child for at least 15 minutes after injection for immediate reactions.
  • Consult a physician for children with compromised immune systems.
  • Pregnancy considerations are not applicable to the pediatric target group but should be noted for future planning.

Avoid Interactions

Havrix Junior may interact with other agents that affect immune function or increase the risk of hypersensitivity.

Avoid

  • Live attenuated vaccines administered within 4 weeks before or after Havrix Junior.
  • Immunoglobulin products given concurrently, which may reduce vaccine response.

Use with caution

  • Immunosuppressive therapy (e.g., corticosteroids) that could diminish antibody formation.
  • Antipyretic or analgesic medications taken prophylactically may mask mild post‑vaccination symptoms.

Frequently Asked Questions

Havrix Junior is approved for use in children aged 12 months and older for primary immunization against hepatitis A.

The vaccine is given as an intramuscular injection, typically into the deltoid muscle.

Algeldrate acts as an adjuvant, enhancing the immune response to the inactivated hepatitis A virus antigen.

Yes, Havrix Junior can be co‑administered with other vaccines when clinical guidelines allow, but timing should follow local immunization schedules.

Common reactions include mild pain, redness or swelling at the injection site, low‑grade fever, headache, and fatigue.

Serious events are rare but may include severe allergic reactions (anaphylaxis), prolonged high fever, or, very rarely, neurological symptoms such as seizures.

Vaccination is generally postponed if the child has a moderate or severe acute illness; mild illness does not usually contraindicate vaccination.

Children with significant immunosuppression should be evaluated by a healthcare professional before receiving the vaccine, as response may be reduced.

Concurrent administration may reduce the vaccine’s effectiveness; a suitable interval should be observed according to clinical guidance.

A mild fever can be managed with age‑appropriate antipyretics and fluids; if fever persists beyond 48 hours or is high, medical advice should be sought.

Health authorities often recommend hepatitis A vaccination for pediatric travelers to regions with intermediate or high endemicity; Havrix Junior fulfills this recommendation.

The standard schedule consists of two doses administered at least six months apart, providing long‑term immunity.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Hepatitis A Virus (Inactivated), Algeldrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT